Orchard Therapeutics Granted FDA Orphan Drug Designation for OTL-102 for X-linked Chronic Granulomatous Disease (X-CGD)
TrialSite News,
Orchard Therapeutics announced the U.S. FDA has granted Orphan Drug Designation for OTL-102, the company’s ex vivo autologous…